APRI (Aprinoia Therapeutics) EBIT per Share: $-0.88 (TTM As of Dec. 2023)


What is Aprinoia Therapeutics EBIT per Share?

Aprinoia Therapeutics APRI EBIT per Share is $-0.88 as of Dec. 2023.

Aprinoia Therapeutics's EBIT per Share for the six months ended in Dec. 2023 was $-0.67. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.88.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Aprinoia Therapeutics's EBIT per Share or its related term are showing as below:

APRI's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.45
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Aprinoia Therapeutics's EBIT for the six months ended in Dec. 2023 was $-18.02 Mil.

Aprinoia Therapeutics  (NAS:APRI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Aprinoia Therapeutics EBIT per Share Related Terms

Aprinoia Therapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics EBIT per Share Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EBIT per Share
-0.83 -1.01 -0.85

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EBIT per Share 0.00 -0.49 -0.52 -0.20 -0.67

Aprinoia Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Aprinoia Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-23.711/27.937
=-0.85

Aprinoia Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

EBIT per Share(Q: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-18.023/26.861
=-0.67

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.88 mean?
Aprinoia Therapeutics (APRI) has a EBIT per Share of $-0.88 as of Dec. 2023. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' EBIT per Share too high?
Aprinoia Therapeutics' current EBIT per Share is $-0.88.
How does Aprinoia Therapeutics' EBIT per Share compare to ?
Aprinoia Therapeutics' EBIT per Share of $-0.88 can be compared against companies in the Biotechnology industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,182 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aprinoia Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprinoia Therapeutics's current EBIT per Share is $-0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current EBIT per Share of $-0.88. The current EBIT per Share is $-0.88. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current EBIT per Share is $-0.88 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.